An injectable medication, Invega® Sustenna® (paliperidone palmitate) is a long-acting drug licensed to treat schizophrenia. This medicine comes in the form of a liquid that is given as an injection into a muscle (an intramuscular, or IM, injection). It is usually given every four weeks and will be administered by a healthcare provider in an office or clinic.
The first two Invega Sustenna injections are given into the shoulder (deltoid muscle). Subsequent injections can be given in the buttocks (gluteal muscle) or shoulder.
(For more details on this medicine, click Invega Sustenna. This Web selection provides a complete overview of this drug, including how it works, possible side effects, and what to discuss with your healthcare provider before beginning treatment.)
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed November 17, 2011.
National Library of Medicine (US). Drugs and Lactation Database (LactMED). NLM Web site. Available at: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT. Accessed November 17, 2011.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click